Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling

Experimental Dermatology

Volumn 24, Issue 7, 2015, Pages 503-509

  Kim, Byung Hak ^a,f   Lee, Yoonji ^b   Yoo, Hyun ^a   Cui, Minghua ^b   Lee, Sungwoon ^c   Kim, Sun Young ^d   Cho, Jong Un ^d   Lee, Hyangsook ^d   Yang, Beom Seok ^e   Kwon, Young Guen ^c   Choi, Sun ^b   Kim, Tae Yoon ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Ewha Womans University   (South Korea)

^c Yonsei University   (South Korea)

^d LegoChem Biosciences Inc ^*  (South Korea)

^e Korea Institute of Science and Technology   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

Author keywords

Angiogenesis; JAK STAT3; LCB03 0110; VEGFR 2

Indexed keywords

(3 (2 (3 (MORPHOLINOMETHYL)PHENYL)THIENO[3,2 B]PYRIDIN 7 YLAMINO) PHENOL; ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; JANUS KINASE; STAT3 PROTEIN; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; 3-(2-(3-(MORPHOLINOMETHYL)PHENYL)THIENO(3,2-B)PYRIDIN-7-YLAMINO)PHENOL; AMINOPYRIDINE DERIVATIVE; CSK TYROSINE-PROTEIN KINASE; PROTEIN TYROSINE KINASE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING SITE; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; ONCOGENE SRC; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG SCREENING; HAIRLESS MOUSE; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; RAT; SECONDARY; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ADENOSINE TRIPHOSPHATE; AMINOPYRIDINES; ANGIOGENESIS INHIBITORS; ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; JANUS KINASES; LUNG NEOPLASMS; MALE; MICE; MICE, HAIRLESS; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; PROTEIN STRUCTURE, SECONDARY; RATS; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR; THIOPHENES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931411333     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12698     Document Type: Article

References (45)

1. Risau W, Flamme I. Annu Rev Cell Dev Biol 1995: 11: 73-91.
2. Folkman J. N Engl J Med 1971: 285: 1182-1186.
3. Krock B L, Skuli N, Simon M C. Genes Cancer 2011: 2: 1117-1133.
4. Roskoski R Jr. Crit Rev Oncol Hematol 2007: 62: 179-213.
5. Ferrara N, Gerber H P, LeCouter J. Nat Med 2003: 9: 669-676.
6. Olsson A K, Dimberg A, Kreuger J et al. Nat Rev Mol Cell Biol 2006: 7: 359-371.
7. Holmes K, Roberts O L, Thomas A M et al. Cell Signal 2007: 19: 2003-2012.
8. Schindler C, Shuai K, Prezioso V R et al. Science 1992: 257: 809-813.
9. Shuai K, Ziemiecki A, Wilks A F et al. Nature 1993: 366: 580-583.
10. Kiu H, Nicholson S E. Growth Factors 2012: 30: 88-106.
11. O'Shea J J, Holland S M, Staudt L M. N Engl J Med 2013: 368: 161-170.
12. Kim Y, Kim B H, Lee H et al. Free Radic Biol Med 2011: 51: 1985-1995.
13. Baker M, Robinson S D, Lechertier T et al. Nat Protoc 2011: 7: 89-104.
14. Hasegawa M, Nishigaki N, Washio Y et al. J Med Chem 2007: 50: 4453-4470.
15. Cowan-Jacob S W, Fendrich G, Manley P W et al. Structure 2005: 13: 861-871.
16. Luke R W, Ballard P, Buttar D et al. Bioorg Med Chem Lett 2009: 19: 6670-6674.
17. Blake J F, Kallan N C, Xiao D et al. Bioorg Med Chem Lett 2010: 20: 5607-5612.
18. Kinoshita T, Yoshida I, Nakae S et al. Biochem Biophys Res Commun 2008: 377: 1123-1127.
19. Aronov A M, Tang Q, Martinez-Botella G et al. J Med Chem 2009: 52: 6362-6368.
20. Sun X, Phan T N, Jung S H et al. J Pharmacol Exp Ther 2012: 340: 510-519.
21. Le Boeuf F, Houle F, Huot J. J Biol Chem 2004: 279: 39175-39185.
22. Mehta R R, Yamada T, Taylor B N et al. Angiogenesis 2011: 14: 355-369.
23. Saraswati S, Kumar S, Alhaider A A. Mol Cancer 2013: 12: 147.
24. Kujawski M, Kortylewski M, Lee H et al. J Clin Invest 2008: 118: 3367-3377.
25. Kamran M Z, Patil P, Gude R P. Biomed Res Int 2013: 2013: 421821.
26. Jung J E, Lee H G, Cho I H et al. FASEB J 2005: 19: 1296-1298.
27. Kang S H, Yu M O, Park K J et al. Neurosurgery 2010: 67: 1386-1395.
28. Carbajo-Pescador S, Ordoñez R, Benet M et al. Br J Cancer 2013: 109: 83-91.
29. van Cruijsen H, Giaccone G, Hoekman K. Int J Cancer 2005: 117: 883-888.
30. Tabernero J. Mol Cancer Res 2007: 5: 203-220.
31. Calvi C, Dentelli P, Pagano M et al. Arterioscler Thromb Vasc Biol 2004: 24: 511-518.
32. Eklund L, Olsen B R. Exp Cell Res 2006: 312: 630-641.
33. Shim W S, Ho I A, Wong P E. Mol Cancer Res 2007: 5: 655-665.
34. Nishida N, Yano H, Nishida T et al. Vasc Health Risk Manag 2006: 2: 213-219.
35. Weis S M, Cheresh D A. Nat Med 2011: 17: 1359-1370.
36. Velasco P, Lange-Asschenfeldt B. Br J Dermatol 2002: 147: 841-852.
37. Yano K, Kajiya K, Ishiwata M et al. J Invest Dermatol 2004: 122: 201-208.
38. Odorisio T, Cianfarani F, Failla C M et al. J Dermatol Sci 2006: 41: 11-19.
39. Meissner M, Reichenbach G, Stein M et al. Cancer Res 2009: 69: 1976-1984.
40. Mendel D B, Laird A D, Xin X et al. Clin Cancer Res 2003: 9: 327-337.
41. Haftchenary S, Avadisian M, Gunning P T. Anticancer Drugs 2011: 22: 115-127.
42. Debnath B, Xu S, Neamati N. J Med Chem 2012: 55: 6645-6668.
43. Mascarenhas J, Mughal T I, Verstovsek S. Curr Med Chem 2012: 19: 4399-4413.
44. Faivre S, Djelloul S, Raymond E. Semin Oncol 2006: 33: 407-420.
45. Peng X, Pentassuglia L, Sawyer D B. Circ Res 2010: 106: 1022-1034.